Table 3 Reactome pathways significantly associated with progression of IgAN. Up-regulated pathways tested by including proteins with significantly higher abundance in progressive vs non-progressive IgAN, and down-regulated pathways by including proteins with significantly lower abundance
From: Proteomic signature of tubulointerstitial tissue predicts prognosis in IgAN
Pathway name | N proteins changed abundance | P-value | FDR adjusted p-value |
|---|---|---|---|
Up-regulated pathways | |||
Immune System | 23 | 0.001 | 0.04 |
Innate Immune System | 18 | 0.0001 | 0.01 |
Neutrophil degranulation | 12 | 0.00002 | 0.01 |
Signaling by Interleukins | 10 | 0.00002 | 0.03 |
Signaling by Rho GTPases | 10 | 0.0002 | 0.02 |
RHO GTPase Effectors | 9 | 0.00006 | 0.01 |
Vesicle-mediated transport | 12 | 0.001 | 0.04 |
Down-regulated pathways | |||
Metabolism of proteins | 23 | 0.02 | 0.3 |
Translation | 18 | 4.5E-12 | 1.78E-09 |
Mitochondrial translation | 10 | 2.2E-9 | 2.95E-07 |
tRNA Aminoacylation | 5 | 0.00002 | 0.001 |
Mitochondrial tRNA aminoacylation | 3 | 0.0005 | 0.023 |
Protein localization | 6 | 0.001 | 0.053 |
Mitochondrial protein import | 3 | 0.01 | 0.2 |